Mitchell L Shiffman

Summary

Publications

  1. doi request reprint Treatment of hepatitis C in 2011: what can we expect?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Mary Immaculate Hospital Medical Pavilion suite 313, Newport News, VA 23602, USA
    Curr Gastroenterol Rep 12:70-5. 2010
  2. doi request reprint Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA 23662, USA
    Liver Int 32:54-60. 2012
  3. doi request reprint Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA 23226, USA
    Liver Int 33:105-10. 2013
  4. doi request reprint Interferon-free regimens: the near future, the likely and the not so likely
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Newport News, VA 23602, USA
    Clin Liver Dis 15:665-75. 2011
  5. doi request reprint HCV F1/F2 patients: treat now or continue to wait
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA, USA Sercive d H├ępatologie, Hopital Pitie Salpetriere, Paris, France
    Liver Int 34:79-84. 2014

Detail Information

Publications5

  1. doi request reprint Treatment of hepatitis C in 2011: what can we expect?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Mary Immaculate Hospital Medical Pavilion suite 313, Newport News, VA 23602, USA
    Curr Gastroenterol Rep 12:70-5. 2010
    ....
  2. doi request reprint Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA 23662, USA
    Liver Int 32:54-60. 2012
    ..The latter is highly dependent upon IFN sensitivity and the IL28B genotype...
  3. doi request reprint Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA 23226, USA
    Liver Int 33:105-10. 2013
    ..The factors which should be considered when deciding whether to treat a patient with HCV and mild fibrosis with the current SOC now, or to delay treatment until less toxic and/or more effective therapy is available is discussed...
  4. doi request reprint Interferon-free regimens: the near future, the likely and the not so likely
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Newport News, VA 23602, USA
    Clin Liver Dis 15:665-75. 2011
    ..This article reviews the mechanisms through which interferon is believed to suppress HCV and lead to SVR. These observations are used to speculate as to whether an all-oral antiviral cocktail could "cure" HCV in the near future...
  5. doi request reprint HCV F1/F2 patients: treat now or continue to wait
    Mitchell L Shiffman
    Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, Richmond, VA, USA Sercive d H├ępatologie, Hopital Pitie Salpetriere, Paris, France
    Liver Int 34:79-84. 2014
    ..The factors which should be considered when deciding whether to treat a patient with HCV now or to delay treatment until IFN free therapies are available is discussed. ..